Literature DB >> 2452953

Acute phase proteins in chronic and malignant liver diseases.

R Meliconi1, O Parracino, A Facchini, A M Morselli-Labate, F Bortolotti, F Tremolada, M Martuzzi, F Miglio, G Gasbarrini.   

Abstract

Six acute phase proteins (haptoglobin, alpha 1-acid glycoprotein, alpha 1-antitrypsin, alpha 2-macroglobulin, C reactive protein and transferrin) have been measured in the sera of chronic liver disease (CLD) patients with different aetiology (viral, autoimmune and alcoholic) and histology (steatosis, chronic persistent hepatitis, chronic active hepatitis, cirrhosis), and in patients with liver cancer. 1) The most striking changes concerned alpha 2-macroglobulin (increased) and haptoglobin (decreased) levels. 2) Transferrin was lower in alcoholic liver disease than in viral CLD, CRP was lower in autoimmune than in viral or alcoholic CLD, and alpha 1-acid glycoprotein was lower in viral and alcoholic CLD than in autoimmune CLD. Acute phase protein assay may prove useful in differential diagnosis, particularly when specific markers are not available (autoimmune, non A, non B, alcoholic liver diseases). 3) No significant differences related to aetiology (B, non A non B, D viruses) were observed in viral CLD. 4) Patients who progressed to CLD after acute viral hepatitis type B or non A non B did not show different APP levels from those who had recovered when tested 8-12 months after the acute phase. 5) The pattern of APP changes observed in primary liver cell carcinoma was different from both the cirrhotic pattern and the pattern presented by other tumours with or without liver metastasis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2452953     DOI: 10.1111/j.1600-0676.1988.tb00970.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  8 in total

1.  Fibrinolysis and the bleeding tendency in patients with hepatosplenic schistosomiasis.

Authors:  S A Omran; N A Hussein; A A Mohamed; A H el-Kaliouby; A T Hussein
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

2.  Organ System Network Disruption Is Associated With Poor Prognosis in Patients With Chronic Liver Failure.

Authors:  Yen Yi Tan; Sara Montagnese; Ali R Mani
Journal:  Front Physiol       Date:  2020-08-05       Impact factor: 4.566

3.  Screening and detection of portal vein tumor thrombi-associated serum low molecular weight protein biomarkers in human hepatocellular carcinoma.

Authors:  Ji-Gang Qiu; Jia Fan; Yin-Kun Liu; Jian Zhou; Zhi Dai; Cheng Huang; Zhao-You Tang
Journal:  J Cancer Res Clin Oncol       Date:  2007-09-08       Impact factor: 4.553

4.  Altered glycosylation, expression of serum haptoglobin and alpha-1-antitrypsin in chronic hepatitis C, hepatitis C induced liver cirrhosis and hepatocellular carcinoma patients.

Authors:  Gautam Mondal; Ashish Saroha; Partha Pratim Bose; B P Chatterjee
Journal:  Glycoconj J       Date:  2016-03-31       Impact factor: 2.916

Review 5.  C-reactive protein and bacterial infection in cirrhosis.

Authors:  Giulia Pieri; Banwari Agarwal; Andrew K Burroughs
Journal:  Ann Gastroenterol       Date:  2014

6.  A prospective follow-up study of the relationship between high-sensitivity C-reactive protein and primary liver cancer.

Authors:  Sarah Tan Siyin; Tong Liu; Wenqiang Li; Nan Yao; Guoshuai Xu; Jun Qu; Yajun Chen
Journal:  BMC Cancer       Date:  2020-11-30       Impact factor: 4.430

7.  More Pronounced Hypercoagulable State and Hypofibrinolysis in Patients With Cirrhosis With Versus Without HCC.

Authors:  Marco Senzolo; Paolo Simioni; Alberto Zanetto; Elena Campello; Cristiana Bulato; Sabrina Gavasso; Graziella Saggiorato; Sarah Shalaby; Luca Spiezia; Umberto Cillo; Fabio Farinati; Francesco Paolo Russo; Patrizia Burra
Journal:  Hepatol Commun       Date:  2021-08-16

8.  The Diagnostic and Prognostic Values of C-Reactive Protein and Procalcitonin during Bacterial Infections in Decompensated Cirrhosis.

Authors:  Sana Khedher; Nasreddine Fouthaili; Amira Maoui; Sirine Lahiani; Mohamed Salem; Kahena Bouzid
Journal:  Gastroenterol Res Pract       Date:  2018-12-30       Impact factor: 2.260

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.